New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing ...

BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through ...

PPIs like omeprazole (Prilosec) and esomeprazole (Nexium) are widely used to treat heartburn and acid reflux. Long-term use ...

Net revenue for the three months ended March 31, 2025, was approximately $0.3 million, reflecting sales of the QUELIMMUNE ...

A new scientific study identified taurine, which is made naturally in the body and consumed through some foods, as a key ...

Medically reviewed by Alex Yampolsky, PharmD Magnesium chloride is a form of magnesium salt used as a supplement for people ...

Most cases of black toenails aren’t serious, but often require treatment. If you have pain, swelling, or inflammation that’s ...

Alarming studies reveal energy drinks, popular among young individuals in the UK (31%), pose significant health risks.

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC. Unicycive continues to ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three ...

Cardiovascular diseases (CVD) account for 24.8% of all deaths in India, with an age-standardized death rate of 272 per ...